1Kurul S, Saip P, Aydin T. Totally implantabIe venous -access ports: local problems d extr Vtion injuryE J l. Lancet Onco1,2002 ,3 ( 11 ) :684 - 692.
2de Jonge RC, Polderman KH, Gemke 1. Central venous catheter use in the pediatric patient: mechanical and infectious complications J ]. Pediatr Crit Care Med,2005,6 ( 3 ) :329 - 339.
3Schwarz RE, Groeger JS, Coit DG. Subcutaneously implanted central venous access devices in cancer pativnts:a prospective anlysis[ J. Canvcer, 1997 i79 (8): 1635 - 1640.
4Masci G, Magagnoli M, Zucali PA, et al. Minidose Wa.l'arin prophy- laxis for catheter - associated thrombosis in cancer patients:can it be safely associated with fluorouraeil - based chemotherapy[ J]. J Clin Onco1,2003,21 (4) :736 -739.
5Caers J, Fontaine C, Vinh - Hung V ,et al. Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous in- fusion ports[ j ]. Support Care Cancer,2005,13 (5) :325 - 331.
6Kener C, Kirkbam F, Niedemtadt T, et al. Risk facto for current venous thromboemlism in the European collaborative paediatric data- base on cerebra] venous thrombosis:a multicentre cohort study[ J]. Lancet Neurol,2007,6(7) :595 -603.
7Verso M, AgneUi G, Bertoglio S, et aL Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double - blind, placebo - controlled, randomized study in cancer patients[ Jl. J Clin Oncol,2005,23(18) :4057 -4062.
8Levine M, Kakkar AK: Catheter - associated thrombosis: thrombo- prophylaxis or not[J]. J Clin 0ncol,2005,23(18) :4006 -4008.
9Kroger K, Grutter R, Rudofsky G, et al. Follow - up after port - a - oath - induced thrombosiS J]. J Clin Onco1,2002,20(10) :2605 - 2606.
10Bifl'i R, de Braud F, Orsi F,et al. Totally implantable central ve- nous access ports for long - term chemotherapy. A prospective study analyzing complications and costs of 333 devlees with a mini- mum follow -up of 180 days[J]. Ann Oneal,1998,9(7) :767 - 773,.
7Kurul S, Saip P, Aydin T. Totally implantable venous-access-ports : local problems and extravasation injury. Lancet OncoI, 2002, 3 ( 11 ) :684-692.
8Biffi R, Pozzi S, Agazzi A, et al. Use of totally implantable central venous access ports for high dose chemotherapy and peripheral blood stem cell transplantation: resuhs of a monocentre series of 376 patients. Ann Oncol,2004,15(2) :296-300.
9Vescia S, Baumgartnet AK, Jacobs VR, et al. Management of venous port systems in oncology : a review of current evidence. Ann Oneo1,2008,19 ( 1 ) :9-15.
10Kreis H, et al. Patientsttitudes to totally implantable venous access port systems for gynecological or breast malignancies. European Journal of Surgical Ontology(EJSO) ,2007,33( 1 ) :39-43.
